US Bancorp DE Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

US Bancorp DE lowered its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 15.3% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 3,173 shares of the biotechnology company’s stock after selling 573 shares during the period. US Bancorp DE’s holdings in Sarepta Therapeutics were worth $203,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Byrne Asset Management LLC purchased a new position in Sarepta Therapeutics in the 1st quarter valued at $30,000. Center for Financial Planning Inc. purchased a new position in Sarepta Therapeutics in the 1st quarter valued at $31,000. Logan Capital Management Inc. purchased a new position in Sarepta Therapeutics in the 4th quarter valued at $61,000. UMB Bank n.a. lifted its holdings in Sarepta Therapeutics by 53.0% in the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 276 shares in the last quarter. Finally, Hurley Capital LLC increased its stake in shares of Sarepta Therapeutics by 139.2% in the 1st quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 835 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $21.81 on Friday. The company has a market cap of $2.13 billion, a P/E ratio of -25.07 and a beta of 0.46. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The stock has a 50-day moving average of $19.75 and a two-hundred day moving average of $53.96. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $144.22.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $0.89 by $1.13. The company had revenue of $611.09 million during the quarter, compared to the consensus estimate of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%. Sarepta Therapeutics’s revenue was up 68.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.07 EPS. As a group, analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on SRPT shares. Mizuho reaffirmed a “neutral” rating and issued a $14.00 target price (down from $40.00) on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Evercore ISI downgraded Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 target price for the company. in a research note on Thursday, May 8th. Wolfe Research started coverage on Sarepta Therapeutics in a research note on Tuesday, June 17th. They issued a “peer perform” rating for the company. Jefferies Financial Group cut their target price on Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Thursday, July 24th. Finally, BMO Capital Markets raised their target price on Sarepta Therapeutics from $25.00 to $50.00 and gave the stock a “market perform” rating in a research note on Tuesday, July 29th. Six analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Hold” and a consensus price target of $43.63.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.